Nykode Therapeutics’ Post

Aug 17 is World Pancreatic Cancer Awareness Day 💜 Pancreatic cancer often progresses without noticeable symptoms, and by the time signs appear, the cancer has usually spread. The survival rate for distant-stage pancreatic cancer is just 3%. Detecting pancreatic cancer early is crucial. It opens the door to more treatment options and offers a much higher chance of survival 💪 🔗 Learn more about Pancreatic cancer: Cancer.net 🔗Learn more about Geneseeq’s solutions for Pancreatic cancer: https://lnkd.in/gVfNh6u2 🔗Learn more about Geneseeq’s solutions for early cancer detection: https://lnkd.in/gM_bJVGK #NGS #oncology #precisionmedicine #targetedtherapy #Geneseeq #Pancreatic #cancer

Today is World Ovarian Cancer day! The term 'ovarian cancer' is often used to describe cancers that originate in the ovary, fallopian tube, or peritoneum. About 90% of ovarian cancer cases are epithelial cancers, which commonly begin in the fallopian tube. Overall, ovarian cancer ranks as the fifth most common cause of cancer-related death among women in the United States. In 2020, an estimated 207,252 people worldwide died from ovarian cancer. Learn more about ovarian cancer: cancer.net  Learn more about Geneseeq’s solutions: https://lnkd.in/g7mwRY5d #NGS #oncology #precisionmedicine  #targetedtherapy #Geneseeq #ovariancancer

Join us for an informative webinar as we delve into the intricacies of PD-L1 assessment in breast and cervical cancer specimens. In this session, we will provide a comprehensive overview of PD-L1, including its significance in cancer immunotherapy, different assessment types, and explore different specimen types encountered in everyday practice. Throughout the webinar, gain valuable insights into PD-L1 assessment methodologies and their application in breast and cervical cancer diagnostics. Real-life examples and case studies will be used to enhance understanding and facilitate interactive learning. Don't miss this opportunity to deepen your understanding of PD-L1 assessment in breast and cervical cancer specimens. Register now to secure your spot! https://bit.ly/3XuzIKN #PDL1 #CompanionDiagnostics #22C3 #Immunotherapy #PrecisionMedicine #PrecisionOncology #Biomarkers D0115912_1.00

Join us for an informative webinar as we delve into the intricacies of PD-L1 assessment in breast and cervical cancer specimens. In this session, we will provide a comprehensive overview of PD-L1, including its significance in cancer immunotherapy, different assessment types, and explore different specimen types encountered in everyday practice. Throughout the webinar, gain valuable insights into PD-L1 assessment methodologies and their application in breast and cervical cancer diagnostics. Real-life examples and case studies will be used to enhance understanding and facilitate interactive learning. Don't miss this opportunity to deepen your understanding of PD-L1 assessment in breast and cervical cancer specimens. Register now to secure your spot! https://bit.ly/3XuzIKN #PDL1 #CompanionDiagnostics #22C3 #Immunotherapy #PrecisionMedicine #PrecisionOncology #Biomarkers D0115912_1.00

Proactive, early #costofcare discussions addressing all costs are key to reducing #financialtoxicity from diagnosis, treatment, #survivorship, and follow-up #financialnavigation #financialdistress #cancercare #healthequity #access #insuranceoptimization #oncology #navigation

Value-Based RCM joins the Lung Cancer Foundation of America in observing World Lung Cancer Day, focusing on the fight against lung cancer through early screening. Due to the absence of noticeable symptoms, lung cancer is often diagnosed when it has already spread beyond the lungs. Treatment options for patients largely depend on the stage at which the cancer is detected. Visit the LCFA for more details on World Lung Cancer Day and how early detection can save lives : https://bit.ly/4bSHGRg

At this year’s ESMO congress, the long-awaited final overall survival in patients with newly diagnosed advanced ovarian cancer treated with the parp-inhibitor niraparib as first-line maintenance therapy was presented. In this MEDtalk, Mansoor Raza Mirza from Rigshospitalet in Denmark, presented the results of the PRIMA trial. He also perspectives the status of treatment of ovarian cancer with immunotherapy. 🔗 Read more about ESMO 2024 here: https://lnkd.in/dP9ADU5Y #ESMO24 #OvarianCancer #Immunotherapy

As #MelanomaAwarenessMonth continues, did you know that as many as half of all patients treated for melanoma will face recurrence?   Despite recent advancements in the treatment of melanoma and other skin cancers, there still remains a significant unmet need for novel therapeutic approaches, particularly for patients living with metastatic melanoma.   At Scancell Ltd, we are dedicated to developing novel #immunotherapies for the treatment of cancer, with our ImmunoBody® cancer vaccines, SCIB1 and iSCIB1+, incorporating melanoma-specific epitopes to increase efficacy in a broad patient-population. We have previously seen exceptional results from the ongoing SCOPE trial, with an objective response rate of 85%, demonstrating the potential of our therapeutic approach to offer better survival outcomes for patients.   To learn more about our novel #CancerVaccine approach: https://lnkd.in/e2NGAR5P   #Melanoma #MelanomaAwareness #Oncology #SkinCancer 

Today is World Lung Cancer Day, a time to raise awareness and support those affected by lung cancer, the leading cause of cancer deaths worldwide. At Freenome, we are developing blood tests to detect lung cancer early, when it is most treatable. The PROACT LUNG Study is intended to validate the clinical performance of a blood-based test for the early detection of lung cancer. We are currently enrolling as many as 20,000 individuals who meet specific criteria. Together, we can drive significant progress in early cancer detection. #WLCD24 #EarlyDetection #Freenome

Published in the Journal for Immunotherapy of Cancer, Dr. Heinz Josef Lenz, Deputy Director for Research Programs at USC Norris, and his team conducted a CheckMate 9X8 trial in which they found that Nivolumab plus standard-of-care therapy showed numerically higher progression-free survival rates after 12 months, a higher response rate, and more durable responses in patients with metastatic colorectal cancer, compared with standard-of-care therapy alone, with acceptable safety. Further investigation to identify subgroups of patients with metastatic colorectal cancer that may benefit from nivolumab plus standard-of-care therapy versus standard-of-care therapy in the first-line setting is warranted. Learn more about this study here: https://lnkd.in/gDfuuiVs.